Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.80 |
| ▸ | INSR | P06213 | 9/20 | 0.80 |
| ▸ | IGF1R | P08069 | 6/20 | 0.80 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.80 |
| ▸ | KIT | P10721 | 7/20 | 0.67 |
| ▸ | FLT3 | P36888 | 6/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | PRKCG | P05129 | 1/20 | 0.60 |
| ▸ | ROS1 | P08922 | 1/20 | 0.60 |
| ▸ | FER | P16591 | 1/20 | 0.60 |
| ▸ | LTK | P29376 | 1/20 | 0.60 |
| ▸ | WEE1 | P30291 | 1/20 | 0.60 |
| ▸ | FRK | P42685 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | MST1R | Q04912 | 1/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.60 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512021 | 0.91 | ALK (0.87) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL3511212 | 0.89 | ALK (1.00) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL18108652 | 0.87 | AURKA (0.72) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL1334861 | 0.86 | KIT (0.87) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL3513873 | 0.84 | ALK (0.79) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL3510258 | 0.84 | ALK (0.87) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL1334910 | 0.83 | KIT (0.86) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL1335749 | 0.83 | KIT (0.86) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL1335053 | 0.83 | FLT3 (0.88) | ALKINSRIGF1RNTRK1AURKA | |
| SCHEMBL591131 | 0.83 | KIT (0.63) | ALKINSRIGF1RNTRK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176231-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-10-19 | — | — | EP | claimed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | claimed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | claimed |
| CN-101754956-A | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2010-06-23 | — | — | CN | claimed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | claimed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | claimed |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| EP-3834827-A1 | N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO) BENZAMIDE FOR TREATING PATIENTS WITH ROS1,NTRK1, NTRK2 AND NTRK3 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3107541-B1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10561651-B2 | Methods for treating neuroblastoma | IGNYTA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-14 | — | — | US | disclosed |
| US-8673893-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-18 | — | — | US | disclosed |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | ALK 401/4885INSR 387/4885IGF1R 188/4885 |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ALK 397/4885INSR 433/4885IGF1R 212/4885 |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | ALK 401/4885INSR 387/4885IGF1R 188/4885 |
| US-10561651-B2 | Methods for treating neuroblastoma | UBTF, CABLES1, WEE2 | ALK 1037/4885INSR 1551/4885IGF1R 299/4885 |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ALK 397/4885INSR 433/4885IGF1R 212/4885 |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ALK 397/4885INSR 433/4885IGF1R 212/4885 |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | ROS1, KRAS, NOX1 | ALK 337/4885INSR 303/4885IGF1R 72/4885 |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | ROS1, KRAS, NOX1 | ALK 337/4885INSR 303/4885IGF1R 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.